Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Tart Cherry, Metabolic Syndrome, and Cardiovascular Risk

This study has been completed.
Sponsor:
Collaborator:
Cherry Research Committee
Information provided by (Responsible Party):
Bahram Arjmandi, Florida State University
ClinicalTrials.gov Identifier:
NCT02154100
First received: May 30, 2014
Last updated: December 6, 2016
Last verified: December 2016
  Purpose
The hypothesis of this study is that the daily consumption of 480 ml tart cherry juice for twelve weeks will improve blood pressure and arterial stiffness by improving endothelial-mediated vasodilation and vascular sympathetic activity and favorably altering biochemical markers associated with cardiovascular risk. 28 men and women between the ages of 20 and 40 who have three of the five features of metabolic syndrome as defined by the Adult Treatment Panel III will be included in the study. After a two-week run-in phase, eligible men and women will be randomly assigned to one of two treatment groups: 1) 480 ml tart cherry juice or 2) 480 ml control drink daily for twelve weeks. After an initial telephone screening, all participants will be requested to report to the study site for their first visit. On the first visit (screening), participants will be provided with verbal and written explanation of the project. They will then be asked to sign an informed consent form, followed by measuring waist circumference, resting brachial blood pressure, fasting serum triglycerides, high density lipoprotein cholesterol, and glucose levels to confirm metabolic syndrome. Baseline assessments will be performed for medical history, medication use, dietary intake, and physical activity. Qualified participants will be scheduled for their second visit two weeks later (actual baseline data collection) and randomly assigned to their treatment group. On the second (baseline) visit between the hours of 7-10 A.M., blood pressure and vascular function will be measured followed by blood draw. Anthropometrics will be measured. Participants will be provided with their assigned treatment and will receive standard instructions on how to fill out daily diaries for their treatment, and for food and physical activity records. Blood pressure, vascular function, blood draw, and anthropometric, body composition, diet, and physical activity assessments will be repeated at 6- (third visit), and 12-week (final visit) intervals. All cardiovascular measurements will be performed between 7:00 to 10:00 A.M., in a quiet temperature-controlled room in the supine position after an overnight fast and 12 hours after the abstinence of caffeine and/or 24 hours after the last bout of moderate to heavy physical activity.

Condition Intervention Phase
Metabolic Syndrome
Cardiovascular Diseases
Diabetes
Dietary Supplement: Tart Cherry
Dietary Supplement: Placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single Blind (Participant)
Primary Purpose: Treatment
Official Title: Tart Cherry Improves Cardiovascular Risk Factors Associated With Metabolic Syndrome

Resource links provided by NLM:


Further study details as provided by Florida State University:

Primary Outcome Measures:
  • Blood Pressure [ Time Frame: 12 weeks ]
    By measuring brachial and aortic blood pressure at rest and during physiological stress (handgrip exercise and post-exercise muscle ischemia).

  • Arterial Stiffness [ Time Frame: 12 weeks ]
    By measuring arterial stiffness and augmentation index at rest and during physiological stress (handgrip exercise and post-exercise muscle ischemia).


Secondary Outcome Measures:
  • Autonomic Control of Blood Pressure [ Time Frame: 12 weeks ]
    By measuring blood pressure variability and baroreflex sensitivity at rest and during physiological stress.

  • Endothelial Function [ Time Frame: 12 weeks ]
    By measuring markers of endothelial function.

  • Endothelial-mediated Vasodilation [ Time Frame: 12 weeks ]
    By measuring flow-mediated dilation in the brachial artery.

  • Inflammation [ Time Frame: 12 weeks ]
    By measuring a marker of inflammation.

  • Oxidative Stress [ Time Frame: 12 weeks ]
    By measuring markers of oxidative stress.

  • Insulin Sensitivity [ Time Frame: 12 weeks ]
    By measuring fasting glucose, insulin, and homeostatic model assessments of insulin resistance, sensitivity, and beta cell function.

  • Atherogenic Markers [ Time Frame: 12 weeks ]
    By measuring adhesion factors, lipid profiles, and atherogenic risk ratios.

  • Body Composition [ Time Frame: 12 weeks ]
    By measuring fat mass and fat-free mass using dual-energy X-ray absorptiometry and anthropometrics.


Enrollment: 26
Study Start Date: April 2014
Study Completion Date: October 2016
Primary Completion Date: October 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Tart Cherry
12 weeks of tart cherry juice taken in two doses of 240 ml per day.
Dietary Supplement: Tart Cherry
12 weeks of tart cherry juice taken in two doses of 240 ml per day.
Placebo Comparator: Placebo
12 weeks tart cherry juice taken in two doses of 240 ml per day.
Dietary Supplement: Placebo
12 weeks of tart cherry juice taken in two doses of 240 ml per day.

  Eligibility

Ages Eligible for Study:   20 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Three of the following five features at the screening visit:
  • Waist circumference of ≥ 40 inches for men and 35 inches for women
  • Serum triglycerides ≥ 150 mg/dL
  • Serum high density lipoprotein cholesterol levels < 40 mg/dL for men and <50 mg/dL for women
  • Blood pressure ≥ 130/85 mm Hg
  • Fasting blood glucose level ≥ 110 mg/dL

Exclusion Criteria:

  • Taking hypoglycemic, antihypertensive or cholesterol-lowering medications
  • Diagnosed cardiovascular disease
  • Uncontrolled hypertension (≥ 160/100 mmHg)
  • Diabetes mellitus
  • Other active chronic diseases such as cancer, asthma, glaucoma, thyroid, kidney, liver and pancreatic disease
  • Participating in a weight loss program
  • Heavy smokers (> 20 cigarettes per day)
  • Heavy drinkers (> 12 alcoholic drinks per week)
  • Abnormal menstrual cycle
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02154100

Locations
United States, Florida
Department of Nutrition, Food and Exercise Sciences, Center for Advancing Exercise and Nutrition Research on Aging, Florida State University
Tallahassee, Florida, United States, 32306
Sponsors and Collaborators
Florida State University
Cherry Research Committee
Investigators
Principal Investigator: Bahram H. Arjmandi, PhD, RD Department of Nutrition, Food and Exercise Sciences, Center for Advancing Exercise and Nutrition Research on Aging, Florida State University
Principal Investigator: Arturo Figueroa, MD, PhD Department of Nutrition, Food and Exercise Sciences, Florida State University
Principal Investigator: Sarah A. Johnson, PhD, RDN Department of Food Science and Human Nutrition, Colorado State University
  More Information

Additional Information:
Responsible Party: Bahram Arjmandi, Professor, Florida State University
ClinicalTrials.gov Identifier: NCT02154100     History of Changes
Other Study ID Numbers: RF02406
Study First Received: May 30, 2014
Last Updated: December 6, 2016

Keywords provided by Florida State University:
Metabolic Syndrome
Arterial Stiffness
Blood Pressure
Endothelial Function
Tart Cherries

Additional relevant MeSH terms:
Syndrome
Cardiovascular Diseases
Metabolic Syndrome X
Disease
Pathologic Processes
Insulin Resistance
Hyperinsulinism
Glucose Metabolism Disorders
Metabolic Diseases

ClinicalTrials.gov processed this record on May 24, 2017